Further research will eventually tell whether non-steroidal mineralocorticoid receptor antagonists, SGLT2 inhibitors, or some other type of treatment with kidney benefits will be suitable for type 1 diabetes. This evidence concerns the gene NR3C2 and type 1 diabetes mellitus.